Viruses 2012, 4(11), 2711-2735; doi:10.3390/v4112711
Review

Advances and Future Challenges in Recombinant Adenoviral Vectored H5N1 Influenza Vaccines

Vaxin Inc, 19 Firstfield Road, Suite 200, Gaithersburg, Maryland 20878, USA
Received: 30 September 2012; in revised form: 22 October 2012 / Accepted: 25 October 2012 / Published: 1 November 2012
(This article belongs to the Section Antivirals & Vaccines)
PDF Full-text Download PDF Full-Text [393 KB, uploaded 1 November 2012 10:02 CET]
Abstract: The emergence of a highly pathogenic avian influenza virus H5N1 has increased the potential for a new pandemic to occur. This event highlights the necessity for developing a new generation of influenza vaccines to counteract influenza disease. These vaccines must be manufactured for mass immunization of humans in a timely manner. Poultry should be included in this policy, since persistent infected flocks are the major source of avian influenza for human infections. Recombinant adenoviral vectored H5N1 vaccines are an attractive alternative to the currently licensed influenza vaccines. This class of vaccines induces a broadly protective immunity against antigenically distinct H5N1, can be manufactured rapidly, and may allow mass immunization of human and poultry. Recombinant adenoviral vectors derived from both human and non-human adenoviruses are currently being investigated and appear promising both in nonclinical and clinical studies. This review will highlight the current status of various adenoviral vectored H5N1 vaccines and will outline novel approaches for the future.
Keywords: recombinant adenoviral vector; influenza vaccine; cross-protection; pandemic influenza; H5N1

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Zhang, J. Advances and Future Challenges in Recombinant Adenoviral Vectored H5N1 Influenza Vaccines. Viruses 2012, 4, 2711-2735.

AMA Style

Zhang J. Advances and Future Challenges in Recombinant Adenoviral Vectored H5N1 Influenza Vaccines. Viruses. 2012; 4(11):2711-2735.

Chicago/Turabian Style

Zhang, Jianfeng. 2012. "Advances and Future Challenges in Recombinant Adenoviral Vectored H5N1 Influenza Vaccines." Viruses 4, no. 11: 2711-2735.

Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert